# Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

Study · id `cardio:ct-nct05845489` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05845489](<https://clinicaltrials.gov/study/NCT05845489>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05845489

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11086 participants.

## Technical summary

Registry record NCT05845489. Randomized; no masking; primary purpose prevention. Start 2023-03-22 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 11086 participants (planned count; ClinicalTrials.gov record NCT05845489, source copy `cardio:ctgov-nct05845489-2025-12-31`, retrieved 2026-10-26)
- Started: 2023-03-22 (actual) (ClinicalTrials.gov record NCT05845489, source copy `cardio:ctgov-nct05845489-2025-12-31`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT05845489, source copy `cardio:ctgov-nct05845489-2025-12-31`, retrieved 2026-10-26)
- Completion: 2031-12-31 (anticipated) (ClinicalTrials.gov record NCT05845489, source copy `cardio:ctgov-nct05845489-2025-12-31`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05845489, source copy `cardio:ctgov-nct05845489-2025-12-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05845489-2025-12-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
- Condition: Coronary Artery Disease
- Intervention (Drug): Clopidogrel treatment group
- Intervention (Other): No antiplatelet or anticoagulant group
- Lead sponsor: Seoul National University Hospital
- Lead sponsor class: OTHER
- Collaborator: Samjin Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY
- Collaborator: CKD Pharmaceutical Limited
- Collaborator class: UNKNOWN
- Collaborator: Hanmi Pharmaceutical co., ltd.
- Collaborator class: OTHER
- Collaborator: Yuhan Pharmaceutical Company
- Collaborator class: UNKNOWN
- Collaborator: Daewoong Pharmaceutical Co. LTD.
- Collaborator class: INDUSTRY
- Collaborator: Dong-A ST Co., Ltd.
- Collaborator class: INDUSTRY
- Collaborator: IlDong Pharmaceutical Co Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)
- Registry lists this organization as a collaborator: Samjin Pharmaceutical Co., Ltd. (`cardio:org-samjin-pharmaceutical-co-ltd`)
- Registry lists this organization as a collaborator: Hanmi Pharmaceutical co., ltd. (`cardio:org-hanmi-pharmaceutical-co-ltd`)
- Registry lists this organization as a collaborator: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)
- Registry lists this organization as a collaborator: Dong-A ST Co., Ltd. (`cardio:org-dong-a-st-co-ltd`)
- Registry lists this organization as a collaborator: IlDong Pharmaceutical Co Ltd (`cardio:org-ildong-pharmaceutical-co-ltd`)

## Provenance

Content hash: de78243bf711578da1f6d19ca61e102e404aa8ca73d54a9330ab3c7cf1435305
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
